Cargando…
Editorial: serum HBV RNA biphasic decline in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues
LINKED CONTENT This article is linked to Liu et al papers. To view these articles, visit https://doi.org/10.1111/apt.15890 and https://doi.org/10.1111/apt.15993
Autores principales: | Ding, Yang, Dou, Xiaoguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496356/ https://www.ncbi.nlm.nih.gov/pubmed/32852825 http://dx.doi.org/10.1111/apt.15975 |
Ejemplares similares
-
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022) -
Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
por: Li, Yue, et al.
Publicado: (2021) -
Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
por: Broquetas, Teresa, et al.
Publicado: (2017) -
Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
por: Van Hees, Stijn, et al.
Publicado: (2019) -
Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
por: He, Dengming, et al.
Publicado: (2013)